News and Resources
News and resources
The UK's pioneering role in IFFIm: Building on a legacy and continuing to lead*
For decades, the United Kingdom has been a champion of global health—especially in its efforts to find innovative solutions to ensure life-saving vaccines reach those who need them most. At the heart of this commitment is the International Finance Facility for Immunisation (IFFIm), an initiative forged by the UK to revolutionise global health finan...
Board members highlight IFFIm’s value at high-profile events in spring 2025
This spring, IFFIm Board members Rachel Turner and Ingrid van Wees took center stage at major global events, emphasising the power of innovative finance in a pivotal moment for global immunisation. Their discussions underscored how IFFIm’s model transforms long-term donor commitments into immediate funding, allowing donors to achieve rapid impact, ...
IFFIm increases its most recent bond by US$ 250 million to total US$ 1.25 billion
This week, the International Finance Facility for Immunisation (IFFIm) increased by US$ 250 million the October 2024 bond, which had previously raised US$1 billion.
"A wonderful development": in malaria-plagued northern Nigeria, the vaccine’s arrival brings joy
The emotional and financial distress of having a child down with malaria is regrettably familiar to residents of Kaura community in Kebbi state, who hope that’s set to change.
Fighting deadly disease on Uganda’s tea plantations
Tea-picking communities are home to more than their share of unimmunised children. An outreach project is changing that.
After pandemic setback and natural disasters, Malawi school teachers help dial up HPV vaccine uptake
The government’s strategy of training up teachers to explain the science to confused or worried parents is working, learns Ashley Simango.
IFFIm finances Gavi’s groundbreaking malaria vaccine programme
Gavi’s achievements in rolling out the malaria vaccine are a historic breakthrough in the fight against one of the world's deadliest diseases. With critical, flexible financing from IFFIm, the malaria vaccine will protect millions of young lives and reshape health systems in malaria-prone regions.
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.